Called “Biotech Wunderkind” Vivek Ramaswamy Opens First Office in Cambridge

0
661
Vivek Ramaswamy on the cover of Forbes

BOSTON—Called “Biotech Wunderkind” by many, 31-year-old Vivek Ramaswamy, whose company Roivant Sciences has launched five biotech companies, has opened his first office in Cambridge, MA, Boston Business Journal reported.

Roivant Sciences CEO Ramaswamy has been featured on the cover of Forbes magazine, and has founded five biotech companies, two of which have gone public.

“His strategy involves snatching up promising molecules that have been abandoned by Big Pharma, and pushing them through clinical trials,” Boston Business Journal reported. “Now, Ramaswamy is making his first official foray into Cambridge, where he studied at Harvard as an undergrad. One of his ventures, rare disease-focused Enzyvant, recently opened a 4,000 square-foot office at 90 Broadway in Kendall Square, a spokeswoman for the company said.”

Vivek Ramaswamy on the cover of Forbes

In a statement to the Boston Business Journal, Ramaswamy said that Roivant is recruiting on the campuses of Harvard and MIT. The company already has partnerships with two local drugmakers: Boston-based Vertex Pharmaceuticals and Takeda, which has a large presence in Cambridge, reported Boston Business Journal.

The local business newspaper quoted Ramaswamy as saying: “Given the rapid expansion of Roivant, we were destined to eventually set up an office in Boston – one of the leading biotech hubs in the world, surrounded by top-tier research universities and innovative companies.”

Ramaswamy founded Roivant in 2014. Since then, the private Swiss company has spawned five biotechs, each focused on a different area of drug development. The “Vants,” as they are called, include publicly-traded Axovant (NYSE: AXON) and Myovant (NYSE: MYOV), which focus on neurological diseases and women’s health, respectively. The others are Enzyvant, Dermavant (dermatology) and Urovant (urology), according to Boston Business Journal.

LEAVE A REPLY

Please enter your comment!
Please enter your name here